Despite commercial opportunities, safety issues hinder the growth of acute heart failure drug market

MUMBAI, India - Jan. 13, 2015 - PRLog -- There is no defined need for new treatments for heart failure, especially because mortality and morbidity rates are already improving. However, heart failure remains the leading cause of hospitalization for patients over the age of 65 in the western countries. Moreover, aging population in these markets also has increased the prevalence of the disease and increased healthcare expenditure. Despite the high levels of unmet needs in both chronic and acute heart failure, the pipeline review for acute heart failure is relatively weak. With the recent slew of failures in the pipeline reviews, market research forecasted only USD 1 billion as revenues generated from novel pipeline. Of all the products, Tolvaptan is the most promising one in acute heart failure pipeline, especially after the recent disappointing results from rivals with Levosimendan.

This report, Acute Heart Failure - Pipeline Review, H2 2014, provides comprehensive information on the therapeutic development for acute heart failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for acute heart failure and special features on late-stage and discontinued projects.

Market overview

Currently, the late stage heart failure pipeline is weak, especially in terms of quantity and quality, because 81% of products in the clinical trial are either in Phase I or Phase II of their development process. The majority of the pipeline products that are currently being developed are for chronic heart failure, of these only 33% are being developed for acute heart failure.

Moreover, development of chronic heart failure products are currently holding much commercial promise because they are primarily being developed as add-on therapies with niche focused launch strategies. They are also trying to increase the use of medical devices in this area to form strong competition. The acute heart failure pipeline has good commercial potential, but various kinds of safety issues have led to disappointments, especially for Levosimendan, which left only Tolvaptan as the only promising acute heart failure product in the pipeline.